US Bancorp’s Neuronetics STIM Stock Holding History

US Bancorp’s Portfolio STIM Stock Details STIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-250	Closed	-$1K	–	4194
2021 Q4	$1K	Buy	+250	New	+$1.22K	﹤0.01%	4029

Other funds holding STIM

Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

US Bancorp's STIM Position: Q1 2022 in Review

US Bancorp sold out of Neuronetics (STIM) in Q1 2022, closing a stake of 250 shares — an estimated $1K sold.

US Bancorp first reported a position in STIM in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 83 funds tracked by Wall St. Rank hold STIM as of Q1 2022.

US Bancorp reported no remaining Neuronetics position as of Q1 2022 after selling out during the quarter.
US Bancorp sold 250 Neuronetics shares in Q1 2022, an estimated $1K.
US Bancorp first reported a position in Neuronetics in Q4 2021 and held it in 1 quarter.
US Bancorp's Neuronetics position peaked at $1K in Q4 2021.
83 funds tracked by Wall St. Rank held Neuronetics as of Q1 2022.

Based on US Bancorp's 13F filing for Q1 2022, filed 11 May 2022.